Aug. 1 Company Quick Takes: Nektar gains on breakthrough for NKTR-214; plus Adaptive's MRD test, Acadia, Vanda and more

Nektar gains after FDA breakthrough therapy designation
Nektar Therapeutics Inc. (NASDAQ:NKTR) was up $2.73 (10%) to $31.19 after FDA granted breakthrough designation for bempegaldesleukin (NKTR-214) in combination with Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) for patients with previously untreated unresectable or metastatic melanoma. The companies are co-developing the combo

Read the full 491 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE